Companies › Mirum Pharmaceuticals
4 active drug programs in 11 registered trials: 6 Phase 2, 3 Phase 3, 1 Phase 4, 1 Phase 1; Gastroenterology, Infectious disease, Respiratory, Other; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Maralixibat Ileal bile acid transporter inhibitor | SLC10A2 | Phase 4 | Alagille Syndrome; Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC); Constipation Chronic Idiopathic | Feb 2027 |
| Brelovitug (BJT-778) NTCP (sodium taurocholate cotransporting polypeptide) inhibitor | NTCP | Phase 3 | Chronic Hepatitis D Infection; Chronic Hepatitis D | Jun 2027 |
| Volixibat Ileal bile acid transporter inhibitor | SLC10A2 | Phase 2 | Primary Biliary Cholangitis; Primary Sclerosing Cholangitis | Jan 2027 |
| [14C]-MRM-3379 unclear - FMRP pathway modulator for Fragile X Syndrome | – | Phase 2 | Fragile X Syndrome; Healthy Volunteers | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07712718 | [14C]-MRM-3379 | Phase 1 | Healthy Volunteers | Other | Jul 2026 |
| NCT05050136 | Volixibat | Phase 2 | Primary Biliary Cholangitis | Gastroenterology | Jan 2027 |
| NCT06553768 | Maralixibat | Phase 3 | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | Gastroenterology | Feb 2027 |
| NCT07200908 | Brelovitug (BJT-778) | Phase 3 | Chronic Hepatitis D Infection | Infectious disease | Jun 2027 |
| NCT06413368 | Maralixibat | Phase 2 | Constipation Chronic Idiopathic | Respiratory | Jun 2027 |
| NCT07454837 | Brelovitug (BJT-778) | Phase 2 | Chronic Hepatitis D | Infectious disease | Aug 2027 |
| NCT07209462 | [14C]-MRM-3379 | Phase 2 | Fragile X Syndrome | Other | Oct 2027 |
| NCT04663308 | Volixibat | Phase 2 | Primary Sclerosing Cholangitis | Gastroenterology | Mar 2028 |
| NCT07298330 | Brelovitug (BJT-778) | Phase 3 | Chronic Hepatitis D Infection | Infectious disease | Jan 2029 |
| NCT06907290 | Brelovitug (BJT-778) | Phase 2 | Chronic Hepatitis D Infection | Infectious disease | May 2029 |
| NCT07290257 | Maralixibat | Phase 4 | Alagille Syndrome | Gastroenterology | Sep 2030 |
Cash and short-term investments of $374m on 2026-09-30; operating cash outflow about $372m a year; runway about 12 months at that burn, to Oct 2027; 5 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 15 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Albireo, an Ipsen Company Inventiva Pharma Biocodex Beijing Continent Pharmaceutical Insmed
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.